BM213

BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury[1].

Product Specifications

CAS Number

[2891606-02-1]

UNSPSC

12352209

Target

Apoptosis; Complement System; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bm213.html

Purity

99.81

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC([C@@H](NC([C@@H](C)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@@H]1CCCN1C([C@@H](NC([C@H](CC2=CC=CC=C2)NC(C)=O)=O)CCCCN[H])=O)=O)=O)=O)=O)=O)CCCNC(N)=N)=O

Molecular Formula

C43H70N12O10

Molecular Weight

915.09

References & Citations

[1]Zhang M, et al. 13-methylpalmatine alleviates myocardial ischemia/reperfusion injury by potentially targeting the C5a-C5aR1 axis to inhibit neutrophil extracellular trap formation. Redox Biol. 2025 Aug 5;86:103802. |[2]Gorman DM, et al. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. J Med Chem. 2021 Nov 25;64 (22) :16598-16608.